Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday November 12, 2009

DrStockPick.com Stock Report!

COV, PWRM

**************************************************************

COV, Covidien Plc

COV is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. COV manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies.

COV launched DuraSeal™ spine sealant, the first product approved by the U.S. Food and Drug Administration (FDA) for intra-operative sealing of the dural membrane during spine procedures. Nearly 1.5 million spine surgeries are performed in the U.S. every year, with an estimated 10% of these

...

Imaging3 Inc. is a leading provider of advanced technology medical imaging devices. Founded in 1993 by Dean Janes, the Company has developed a breakthrough medical imaging device. This device produces 3D medical diagnostic images of virtually any part of the human body in real-time. Imaging3 Inc. trades on the OTC Bulletin Board. They have their headquarters in Burbank, California.

The 3D images, instantly constructed in real-time, are useable for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Healthcare workers using Imaging3 devices will be able to instantly view 3D, high-resolution images. The Company intends to use their existing base of operations and channels of distribution to launch their new medical imaging devices business, based on this Imaging3 Technology.

The Dominion Volumetric Imaging Scanner (DVIS) is a patented mobile fluoroscopy technology. This product can produce a

...

Wright Medical Group, Inc. (WMGI) recently received the Food and Drug administration (FDA) approval to market its CONSERVE Plus Total Hip Resurfacing System in the U.S. The new system, which has received FDA approval, provides surgeons with a bone-conserving alternative to traditional total hip replacement.   With the FDA approval, Wright Medical can now market CONSERVE Plus in the original femoral and acetabular component configuration in the U.S. as specified in its PreMarket Approval (PMA) application with the FDA. The company also intends to develop additional enhancements to the system. Wright Medical is already marketing its CONSERVE Plus system, which has received FDA approval, with additional features in the international markets.   The CONSERVE Plus system, which has received FDA approval, offers pain relief and restoration of normal hip functions while retaining  maximum of the healthy bone. It preserves future surgery options, including a primary total hip replacement. It ...

AmSurg Corp.'s (AMSG) third-quarter earnings per share came in at 44 cents, slightly above the Zacks Consensus Estimate of 43 cents and the year-ago performance of 39 cents.

Revenues for the quarter increased 11% to $167.8 million compared to $150.7 million in the year ago period. The company reported a 6% rise in net earnings to $13.4 million, compared to $12.6 million in the third quarter of 2008. Third-quarter results included a negative impact from the effect of the revision of the Medicare payment system for ambulatory surgery centers (ASCs).

While the addition of 19 centers in operation during the last twelve months was primarily responsible for the robust growth in revenue, performance of same-center revenues remained lackluster due to the current economic conditions. Additionally, the Medicare rule revision reduced same center revenues by approximately 100 basis points.

Operating margin recorded a decline of 106 basis points to 33.82%, compared to

...

Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

...

Recently, Schering-Plough Corporation (SGP) and Opko Health Inc. (OPK) entered into a deal which would enable Opko to acquire the assets of Schering's neurokinin-1 (NK-1) receptor antagonist program. The companies did not disclose the terms of the agreement. NK-1 receptors are mostly found in the brain.  However, they are also found in other tissues of the body. Their activation causes a release of neurotransmitters and other signaling molecules that play a key role in controlling nausea and vomiting amongst other functions.  The U.S. market for nausea and vomiting drugs is estimated to be in excess of $2 billion. Rolapitant, Schering's lead neurokinin, recently completed mid-stage studies for the prevention of nausea and vomiting due to cancer chemotherapy, surgery and other indications. The company has initiated early-stage studies for another compound in the same class.  As a result of Schering’s $41.1 billion merger agreement with ...

SOME THOUGHTS ON THE PSYCHOLOGY OF TRADING

 

ARE TRADERS BORN OR MADE?:  I like this quote, “A lot of the best traders are stubborn iconoclasts who are willing to challenge conventional wisdom, identify an edge and stick to it. The noise of the world doesn’t deter them from their inner convictions.”

PROFESSIONAL TRADERS MAKE MONEY BY PATIENTLY WAITING:  “Independent traders have the luxury of picking and choosing their trades. They don’t have to trade all of the time. This is their edge. They can wait until the market patterns are working for them.”

BUY HIGH AND SELL LOW:  “Our emotions are not our friends when it comes to investing. Relying on emotions is a quick way to buy high and sell low. This is because people give into their greed when they see everyone else

...

ATS Medical, Inc. (ATSI) yesterday received the CE Mark approval for marketing the ATS CryoMaze 10-S Surgical Cryoablation Probe used for the treatment of cardiac arrhythmias in the European Union.   The new product complements the current ATS CryoMaze Probes by adding a linear cryoablation probe that provides more controlled stiffness. This enables surgeons to have more probe leverage so that they can achieve contact with the targeted tissue that is difficult to reach.   The ATS CryoMaze 10-S Surgical Cryoablation Probe achieves the coldest probe temperatures needed for cardiac arrhythmia surgery. The argon-based cryoablation system can reach a temperature of -1600 Celsius versus nitrous-oxide systems that can achieve temperatures of -650 Celsius only. The colder probe temperatures provide faster and deeper lesions compared to the traditional linear lesions.   The ATS CryoMaze 10-S Surgical Cryoablation Probe can be easily shaped by hand without the need of ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

 

DrStockPick.com Watch List!

My Picks for Tuesday October 13, 2009, are:

**************************************************************

VASC, Vascular Solutions Inc.

VASC is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of five major categories: hemostat (blood clotting) products, extraction (clot removal) catheters, vein products, specialty catheters and access products.

VASC has received Food and Drug Administration clearance to sell the new Guardian II hemostasis valve, which is used in surgery

VASC is the exclusive U.S. distributor for the product, which is made by Ireland-based Zerusa Ltd.

**************************************************************

VNDA, Vanda Pharmaceuticals, Inc.

VNDA is a biopharmaceutical company

...

AngioDynamics, Inc. (ANGO) yesterday reported first quarter fiscal 2010 earnings per share of 9 cents, surpassing the Zacks Consensus Estimate of 8 cents. Earnings per share in the year-ago quarter also reached 9 cents. Sales Net sales in the reported quarter were $50.1 million, increasing 13% year over year. The increase was across all the business segments. On a geographic basis, U.S. sales contributed approximately 90% of total sales and increased roughly 15% year over year. International sales were roughly flat year over year. Peripheral Vascular sales increased 14% year over year to $21.1 million. This was primarily due to the Benephit renal infusion system and Diomed acquisitions. Access sales increased 3% year over year to $16.2 million. Oncology/Surgery sales increased 25% year over year to $12.8 million. Margins Gross margin declined 170 basis points (bps) year over year to 60.2% in the ...